Standing up in public for a broader conception of value in healthcare.

33-40 of 60 News

viewpoint 3/10/17

On the Health Affairs Blog: Claire Laporte Explains the "Patent Dance" for Biosimilars, and the Importance of Trade Secrets Claire Leporte breaks down the pathway provided by the new aBLA patent process for manufacturers of biosimilars, illustrating what's at stake and how it impacts intellectual property laws and the preservation of trade secrets. READ MORE

viewpoint 3/07/17

On the Health Affairs Blog: Bach, Helms and Yu Examine Links Between R&D Costs and Drug Prices Peter Bach, Zachary Helms, and Nancy Yu leverage public data to estimate both the premiums that companies earn and the amount they spend on research, challenging pharmaceutical companies' claims regarding R&D spending. READ MORE

viewpoint 3/02/17

On the Health Affairs Blog: Dubois and Westrich Examine Value Frameworks and Suggest Key Considerations for Improvement Robert Dubois and Kimberly Westrich argue that existing value assessment methods hold promise but require further development along multiple dimensions before use in decision making. READ MORE

viewpoint 2/27/17

On the Health Affairs Blog: Darrow, Kesselheim and Lasky-Su Analyze the Promise, Challenges and Limitations of the Precision Medicine Initiative and Cancer Moonshot Jonathan Darrow, Aaron Kesselheim, and Jessica Lasky-Su outline the promise of the Precision Medicine Initiative and Cancer Moonshot, also pointing out some of the challenges and limitations to success. READ MORE

viewpoint 2/17/17

On the Health Affairs Blog: Galvin and Brennan Suggest Employers Can Take Larger Role in Controlling Drug Costs Robert Galvin and Troyen Brennan examine how employers and pharmacy benefit managers can take a harder line with drug manufacturers to lower drug costs, particularly in regard to controlling launch prices. READ MORE

viewpoint 2/14/17

On the Health Affairs Blog: Mazer and Curfman Focus On 21st Century Cures Act and Lowered Confidence in FDA Approved Drugs and Devices Deborah Mazer and Greogory Curfman discuss provisions in the 21st Century Cures Act that could weaken FDA oversight of medical products and newly approved drugs. READ MORE

viewpoint 2/10/17

On the Health Affairs Blog: Jena and Kamal-Bahl Address Family Spillover Effects Anupam Jena and Sachin Kamal-Bahl discuss the importance of considering benefits to caregivers and family members of patients in addition to the benefits of treatment to patients themselves, when measuring value. READ MORE

viewpoint 2/08/17

Jeroen Jansen in Journal of Clinical Oncology: Network Meta-Analysis Needed To Improve Clinical Oncology Value Framework In his letter to the editor, IVI's Jeroen Jansen argues that the ASCO value framework can be improved by incorporating network meta-analysis. READ MORE